The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data

BACKGROUND: Breast cancer (BC) is largely prevalent worldwide. HER2-positive BC account for roughly 20–25% of all BC cases and has an overall survival lower than other BC. Innovation on BC therapeutics is a constant, but novel therapies have higher costs. Therefore, cost-effectiveness research is es...

Descripción completa

Detalles Bibliográficos
Autores principales: Borges, Andreia, Pereira, Filipa, Redondo, Patrícia, Antunes, Luís, Vieira, Cláudia, Antunes, Pedro, Bento, Maria José, Sousa, Susana, Lopes, José Machado, Rocha-Gonçalves, Francisco, de Sousa, Joaquim Abreu, Pereira, Deolinda Sousa, Borges, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431932/
https://www.ncbi.nlm.nih.gov/pubmed/34505956
http://dx.doi.org/10.1186/s13561-021-00332-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431932/
https://www.ncbi.nlm.nih.gov/pubmed/34505956
http://dx.doi.org/10.1186/s13561-021-00332-0

Ejemplares similares